We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Merck and Co Inc | NYSE:MRK | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.84 | -0.65% | 129.28 | 131.05 | 128.98 | 131.05 | 6,944,970 | 01:00:00 |
From May 2019 to May 2024
By Kimberly Chin
Merck & Co. (MRK) has agreed to acquire the privately held animal health technology provider Antelliq Group from BC Partners for a deal valued at about 2.1 billion euros ($2.37 billion) in cash.
Merck said it would make a cash payment to acquire all the outstanding shares of the company. It would assume roughly EUR1.15 billion in debt.
Antelliq will be a wholly owned and independently run subsidiary of Merck's Animal Health division.
The biopharmaceutical company is looking to expand its animal health business portfolio, particularly toward technology and services. Antelliq provides digital animal identification, traceability and monitoring services for farmers and veterinarians.
The deal is expected to close in the second quarter of 2019.
Write to Kimberly Chin at kimberly.chin@wsj.com
(END) Dow Jones Newswires
December 14, 2018 07:41 ET (12:41 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year Merck Chart |
1 Month Merck Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
